Advertisement

Topics

Boehringer Ingelheim, PureTech to Partner on Cancer Immunotherapies

10:30 EDT 17 Apr 2019 | Genetic Engineering News

Boehringer Ingelheim plans to develop new immuno-oncology treatments for an undisclosed number of targets using PureTech Health’s lymphatic targeting technology for immune modulation, through a collaboration that PureTech said today could generate for it more than $226 million. The companies will initially focus on applying PureTech’s internally-developed lymphatic targeting platform to an unspecified Boehringer Ingelheim […]

The post Boehringer Ingelheim, PureTech to Partner on Cancer Immunotherapies appeared first on GEN - Genetic Engineering and Biotechnology News.

Original Article: Boehringer Ingelheim, PureTech to Partner on Cancer Immunotherapies

NEXT ARTICLE

More From BioPortfolio on "Boehringer Ingelheim, PureTech to Partner on Cancer Immunotherapies"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...